Abstract:Importance Lipoprotein(a) (Lp[a]) is a causal risk factor for cardiovascular disease; however, long-term effects on coronary atherosclerotic plaque phenotype, high-risk plaque formation, and pericoronary adipose tissue inflammation remain unknown. Objective To investigate the association of Lp(a) levels with long-term coronary artery plaque progression, high-risk plaque, and pericoronary adipose tissue inflammation. Design, Setting, and Participants This single-center prospective cohort study included 299 patients with suspected coronary artery disease (CAD) who underwent per-protocol repeated coronary computed tomography angiography (CCTA) imaging with an interscan interval of 10 years. Thirty-two patients were excluded because of coronary artery bypass grafting, resulting in a study population of 267 patients. Data for this study were collected from October 2008 to October 2022 and analyzed from March 2023 to March 2024. Exposures The median scan interval was 10.2 years. Lp(a) was measured at follow-up using an isoform-insensitive assay. CCTA scans were analyzed with a previously validated artificial intelligence–based algorithm (atherosclerosis imaging-quantitative computed tomography). Main Outcome and Measures The association between Lp(a) and change in percent plaque volumes was investigated in linear mixed-effects models adjusted for clinical risk factors. Secondary outcomes were presence of low-density plaque and presence of increased pericoronary adipose tissue attenuation at baseline and follow-up CCTA imaging. Results The 267 included patients had a mean age of 57.1 (SD, 7.3) years and 153 were male (57%). Patients with Lp(a) levels of 125 nmol/L or higher had twice as high percent atheroma volume (6.9% vs 3.0%; P = .01) compared with patients with Lp(a) levels less than 125 nmol/L. Adjusted for other risk factors, every doubling of Lp(a) resulted in an additional 0.32% (95% CI, 0.04-0.60) increment in percent atheroma volume during the 10 years of follow-up. Every doubling of Lp(a) resulted in an odds ratio of 1.23 (95% CI, 1.00-1.51) and 1.21 (95% CI, 1.01-1.45) for the presence of low-density plaque at baseline and follow-up, respectively. Patients with higher Lp(a) levels had increased pericoronary adipose tissue attenuation around both the right circumflex artery and left anterior descending at baseline and follow-up. Conclusions and Relevance In this long-term prospective serial CCTA imaging study, higher Lp(a) levels were associated with increased progression of coronary plaque burden and increased presence of low-density noncalcified plaque and pericoronary adipose tissue inflammation. These data suggest an impact of elevated Lp(a) levels on coronary atherogenesis of high-risk, inflammatory, rupture-prone plaques over the long term.

Lipoprotein-Associated Phospholipase A2 Activity, Ferritin Levels, Metabolic Syndrome, And 10-Year Cardiovascular And Non-Cardiovascular Mortality: Results From The Bruneck Study

Lipoprotein-Associated Phospholipase A(2) And Risk Of Coronary Disease, Stroke, And Mortality: Collaborative Analysis Of 32 Prospective Studies

Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results from the Bruneck Study

Evaluation of lipoprotein-associated Phospholipase A2 in Healthy Chinese Han Adult Serum

Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease

Presence and Progression of arotid and Femoral Atherosclerosis nd Symptomatic Cardiovascular Disease ive-Year Prospective Results From the Bruneck Study

Ambient air pollution and lipoprotein-associated phospholipase A₂ in survivors of myocardial infarction

Association between lipoprotein-associated phospholipase A2 activity and coronary heart disease

Lipoprotein-Associated Phospholipase A 2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults

Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II)

Elevated Plasma Lipoprotein-Associated Phospholipase A(2) Activity is Associated with Plaque Rupture in Patients with Coronary Artery Disease

Pltp Activity is A Risk Factor for Subsequent Cardiovascular Events in Cad Patients under Statin Therapy: the Atherogene Study

Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation

[Lipoprotein-associated phospholipase A2 (Lp-PLA2) : relevant biomarker and therapeutic target?]

Study on relationship of lipoprotein-associated phospholipase A2 expression and atherosclerosis progression

Lipoprotein-Associated Phospholipase A2 Activity and Mass as Independent Risk Factor of Stroke: A Meta-Analysis

Association between Lipoprotein-Associated Phospholipase A_2 and Atherothrombosis Stroke

High Plasma Phospholipid Transfer Protein Levels As a Risk Factor for Coronary Artery Disease

The Correlation Between Lipoprotein-Associated Phospholipase A2 and Severity of Coronary Artery Diseases

Elevated Baseline Plasma Phospholipid Protein (PLTP) Levels Are an Independent Predictor of Long-Term All-Cause Mortality in Patients with Diabetes Mellitus and Known or Suspected Coronary Artery Disease.

Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation